A
Amylyx Pharmaceuticals, Inc. (AMLX)
NMS – Real Time Price. Currency in USD
14.44
-0.44 (-2.96%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
14.44
-0.44 (-2.96%)
At close: May 12, 2026, 4:00 PM EDT
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer |
| Dr. Machelle Manuel Ph.D. | VP & Head of Global Medical Affairs |
| Mr. James M. Frates M.B.A. | Chief Financial Officer |
| Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director |
| Mr. Justin B. Klee | Co-Founder, Co-CEO & Director |
| Mr. Tom Holmes | Chief Technical Operations Officer |
| Ms. Gina M. Mazzariello J.D. | Chief Legal Officer & General Counsel |
| Ms. Linda A. Arsenault | Chief Human Resources Officer |
| Ms. Lindsey Allen | Head of Investor Relations & Communications |
| Ms. Tammy Sarnelli | Global Head of Regulatory Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | amlx-20260507.htm |
| 2026-05-07 | 10-Q | amlx-20260331.htm |
| 2026-04-23 | DEFA14A | amlx-defa14a-2026-additi.htm |
| 2026-04-23 | DEF 14A | amlx-20260422.htm |
| 2026-04-23 | ARS | amlx-ars-2026.pdf |
| 2026-03-24 | 8-K | d49067d8k.htm |
| 2026-03-03 | S-8 | d102493ds8.htm |
| 2026-01-08 | 8-K | d45370d8k.htm |
| 2025-11-06 | 8-K | amlx-20251106.htm |
| 2025-09-10 | 8-K | d947193d8k.htm |